Loading...
Market
What will be Kisunla™'s market share for Alzheimer's treatment in Japan by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Market analysis reports from reputable sources such as IQVIA or Frost & Sullivan
Story
Eli Lilly's Kisunla™ for Early Symptomatic Alzheimer's Approved in Japan
Sep 24, 2024, 11:03 AM
Eli Lilly's Alzheimer's drug, Kisunla™ (donanemab-azbt), has received approval from Japan's health ministry for the treatment of early symptomatic Alzheimer's disease. This approval provides patients with another treatment option following the approval of Eisai and Biogen's Leqembi in September last year. The approval marks a significant breakthrough in the fight against dementia, with over 5 million cases projected in Japan by 2030. Eli Lilly's stock rose +0.2% pre-market following the news.
View original story
Similar markets
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
Kisunla > 50% • 25%
Kisunla 30-50% • 25%
Kisunla 10-30% • 25%
Kisunla < 10% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
21% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
< 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
> 30% • 25%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%